
Aldeyra: A Speculative Buy Amid Reproxalap’s NDA Resubmission
Thesis Based on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)’s imminent catalysts (Reproxalap), considering the company holds $133 million in cash, cash equivalents and marketable securities, as